Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial

Neal D. Shore; Martin Gleave; Ugo De Giorgi; Antti Rannikko; Christopher Pieczonka; Swetha Sridharan; Klaus Brasso; Henry H. Woo; Antonio Gómez‐Caamaño; Jeff Saranchuk; Luke T. Nordquist; Ubirajara Ferreira; Yiyun Tang; Brad Rosbrook; Gabriel P. Haas; Matt Rosales; Fabian Zohren; Jamal Tarazi; Stephen J. Freedland

doi:10.1097/ju.0000000000004890

Abstract

NCT02319837.

Affiliated Institutions

Related Publications

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

James L. Mohler , Emmanuel S. Antonarakis , Andrew J. Armstrong +30 more

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of r...

2019 Journal of the National Comprehensive... 1534 citations

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis , Andrew Martin , Martin R. Stockler +29 more

Enzalutamide was associated with significantly longer progression-free and overall survival than standard care in men with metastatic, hormone-sensitive prostate cancer receivin...

2019 New England Journal of Medicine 1481 citations

Genomic correlates of clinical outcome in advanced prostate cancer

Wassim Abida , Joanna Cyrta , Glenn Heller +40 more

Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent through several comprehensive profiling efforts, but little is known about the impact of...

2019 Proceedings of the National Academy o... 1301 citations

The Influence of Finasteride on the Development of Prostate Cancer

Niranjan Sathianathen

This chapter describes the design, main findings, relevance, and limitations of the landmark Prostate Cancer Prevention Trial (PCPT), which randomized men to finasteride versus ...

2021 Oxford University Press eBooks 2085 citations

CAN DIET IN CONJUNCTION WITH STRESS REDUCTION AFFECT THE RATE OF INCREASE IN PROSTATE SPECIFIC ANTIGEN AFTER BIOCHEMICAL RECURRENCE OF PROSTATE CANCER?

Gordon A. Saxe , James R. Hébert , James Carmody +5 more

Our small study provides evidence that a plant-based diet delivered in the context of MBSR decreases the rate of PSA increase and may slow the rate of tumor progression in cases...

2001 The Journal of Urology 127 citations

Publication Info

Year: 2025
Type: article
Pages: 101097JU0000000000004890-101097JU0000000000004890
Citations: 0
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                    Neal D. Shore, 
                                
                                    Martin Gleave, 
                                
                                    Ugo De Giorgi
                                
                                et al.
                            
                            (2025). 
                            Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial. 
                            The Journal of Urology
                            
                            , 101097JU0000000000004890-101097JU0000000000004890.
                            https://doi.org/10.1097/ju.0000000000004890

Identifiers

DOI: 10.1097/ju.0000000000004890